Evidence map›Paper›PMID 30803706›Full record

Trial reportAmerican journal of kidney diseases : the official journal of the National Kidney Foundation2019

Mineralocorticoid Antagonism and Vascular Function in Early Autosomal Dominant Polycystic Kidney Disease: A Randomized Controlled Trial.

Kristen L Nowak, Berenice Gitomer, Heather Farmer-Bailey, Wei Wang, Mikaela Malaczewski, Jelena Klawitter, Zhiying You, Diana George, Nayana Patel, Anna Jovanovich and 1 more

Registry-linked trialOpen access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in American journal of kidney diseases : the official journal of the National Kidney Foundation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01853553 (Mineralocorticoid Antagonism and Endothelial Dysfunction in Autosomal Dominant Polycystic Kidney), which is not on this map. Cited by 10 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 2 pooled it
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01853553 phase3completednot on this map

Mineralocorticoid Antagonism and Endothelial Dysfunction in Autosomal Dominant Polycystic Kidney

TypeinterventionalSponsorUniversity of Colorado, DenverRan2013 to 2017Enrolled61ConditionsADPKDArmsSpironolactone, Sugar pill
3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 2 syntheses or guidelines pooled it, 28 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Cardiovascular Complications in ADPKD.Kidney international reports · 2025
    Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Kristen L NowakDivision of Renal Diseases and Hypertension, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO. Electronic address: kristen.nowak@ucdenver.edu.
Berenice GitomerDivision of Renal Diseases and Hypertension, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO.
Heather Farmer-BaileyDivision of Renal Diseases and Hypertension, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO.
Wei WangDivision of Renal Diseases and Hypertension, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO.
Mikaela MalaczewskiDivision of Renal Diseases and Hypertension, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO.
Jelena KlawitterDepartment of Anesthesiology, University of Colorado Anschutz Medical Campus, Aurora, CO.
Zhiying YouDivision of Renal Diseases and Hypertension, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO.
Diana GeorgeDivision of Renal Diseases and Hypertension, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO.
Nayana PatelDepartment of Radiology, University of Colorado Anschutz Medical Campus, Aurora, CO.
Anna JovanovichDivision of Renal Diseases and Hypertension, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO; Renal Section, Medical Service, Veteran Affairs Eastern Colorado Health Care System, Denver, CO.
Michel ChoncholDivision of Renal Diseases and Hypertension, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO.
University of Colorado Anschutz Medical Campus · US

Funding

NIH Prior Approval Process ProfessionalUL1TR002535 · NCATS · UNIVERSITY OF COLORADO DENVER · PI SOKOL, RONALD J. · 2018 to 2022
$51.1M
Mineralocorticoid Antagonism and Endothelial DysfunctionR01DK097081 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI CHONCHOL, MICHEL BENJAMIN, GITOMER, BERENICE YOLANDE · 2013 to 2015
$1.0M
Curcumin Therapy to Treat Vascular Dysfunction in Children and Young Adults with ADPKDK01DK103678 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI NOWAK, KRISTEN LYNN · 2015 to 2019
$758k
NCATS NIH HHS UL1 TR002535NIDDK NIH HHS K01 DK103678NIDDK NIH HHS R01 DK097081
6 · The paper itself

Abstract

RATIONALE &

objectiveVascular dysfunction, characterized by impaired vascular endothelial function and increased large-elastic artery stiffness, is evident early in autosomal dominant polycystic kidney disease (ADPKD) and is an important predictor of cardiovascular events and mortality. Aldosterone excess has been implicated in the development of endothelial dysfunction and arterial stiffness, in part by causing increased oxidative stress and inflammation. We hypothesized that aldosterone antagonism would reduce vascular dysfunction in patients with early-stage ADPKD. STUDY

designProspective, randomized, controlled, double-blind, clinical trial. SETTING &

participants61 adults aged 20 to 55 years with ADPKD, estimated glomerular filtration rate ≥ 60mL/min/1.73m

interventionSpironolactone (maximum dose, 50mg/d) or placebo for 24 weeks. OUTCOMES: Change in brachial artery flow-mediated dilation (FMD

results60 participants completed the trial. Participants had a mean age of 34±10 (SD) years, 54% were women, and 84% were non-Hispanic white. Spironolactone did not change FMD LIMITATIONS: Low level of baseline vascular dysfunction; lack of aldosterone measurements.

conclusions24 weeks of aldosterone antagonism reduced systolic blood pressure without changing vascular function in patients with early-stage ADPKD.

fundingNIDDK, NIH National Center for Advancing Translational Sciences, and the Zell Family Foundation.

trial registrationRegistered at ClinicalTrials.gov with study number NCT01853553.

Indexed as

AdultBlood PressureBlood VesselsDouble-Blind MethodFemaleHumansMaleMineralocorticoid Receptor AntagonistsPolycystic Kidney, Autosomal DominantProspective StudiesSpironolactoneYoung AdultMineralocorticoid Receptor AntagonistsSpironolactonealdosterone antagonistAutosomal dominant polycystic kidney disease (ADPKD)cardiovascular diseaseclinical trialendotheliumlarge-elastic artery stiffnessmineralocorticoidoxidative stresspolycystic kidney diseasepulse wave velocity (PWV)randomized controlled trial (RCT)spironolactonevascular dysfunctionvascular endothelial function

Identifiers

PMID30803706
PMCPMC6660387
OpenAlexW2917952065

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.